Want to see AU:VFX full AI Analyst Report?
Top Page
1st Group Ltd.
(Sydney:VFX)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.05
▼(-46.00% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily held down by weak financial performance—deep losses, negative equity, and ongoing cash burn—implying elevated funding and execution risk. Technicals provide some offset via near-term price strength above the 20/50-day averages, but the stock remains below the 100-day average. Valuation is also constrained by negative earnings (negative P/E) and the absence of a dividend yield.
Positive Factors
Revenue Growth Momentum
Reported revenue growth, including a large jump in 2025, suggests the company can win customers and scale top line. Sustained revenue momentum provides room to leverage fixed costs and pursue operational improvements over months, supporting eventual margin recovery if costs are controlled.
Negative Factors
Negative Gross Profit & Deep Losses
A swing to negative gross profit indicates unit economics are broken: revenue does not cover direct costs. This structural profitability issue undermines scalability and will require fundamental changes to pricing, cost structure, or product mix to restore sustainable margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Reported revenue growth, including a large jump in 2025, suggests the company can win customers and scale top line. Sustained revenue momentum provides room to leverage fixed costs and pursue operational improvements over months, supporting eventual margin recovery if costs are controlled.
Read all positive factors
1st Group Ltd. (VFX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.77M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue Growth-5.32%
EPS Growth72.83%
CountryAU
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding86,643,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.39
Price to Sales (P/S)1.48
P/FCF Ratio-1.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
1st Group Ltd. Business Overview & Revenue Model
Company Description
Operating in Australia, Visionflex Group Limited and its associated companies specialize in providing cutting-edge healthcare, telehealth, and remote diagnostic services. The company's portfolio features virtual healthcare systems and specialized ...
How the Company Makes Money
null...
1st Group Ltd. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.46M | 4.19M | 6.65M | 4.47M | 4.83M |
| Gross Profit | -1.76M | -2.42M | 3.94M | 3.41M | 4.83M |
| EBITDA | -3.16M | -3.37M | -1.32M | -3.56M | -6.43M |
| Net Income | -1.31M | -3.19M | -1.83M | -3.66M | -6.82M |
Balance Sheet | |||||
| Total Assets | 2.06M | 3.39M | 2.88M | 4.09M | 4.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 1.89M | 1.16M | 1.44M | 2.01M |
| Total Debt | 83.97K | 2.47M | 13.65M | 12.11M | 4.65M |
| Total Liabilities | 1.91M | 5.22M | 19.76M | 18.73M | 8.16M |
| Stockholders Equity | 151.57K | -1.82M | -8.11M | -6.74M | -3.89M |
Cash Flow | |||||
| Free Cash Flow | -2.33M | -3.19M | -1.38M | -3.68M | -2.82M |
| Operating Cash Flow | -2.32M | -3.16M | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -10.56K | -29.51K | 276.80K | 720.13K | -21.84K |
| Financing Cash Flow | 987.13K | 3.92M | 798.81K | 2.36M | 4.59M |
1st Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$4.77M | -2.79 | 245.46% | ― | -5.32% | 72.83% | |
46 Neutral | AU$11.89M | -2.48 | -218.76% | ― | 76.94% | 42.95% | |
42 Neutral | AU$6.05M | -0.71 | 152.58% | ― | -57.91% | -9.02% | |
41 Neutral | AU$3.53M | 64.96 | 15.41% | ― | -5.76% | 8.00% | |
41 Neutral | AU$6.69M | -2.18 | -44.35% | ― | -32.09% | 34.85% |
* Healthcare Sector Average
AU:VFX
1st Group Ltd.
0.06
-0.02
-27.63%
AU:GLH
Global Health Limited
0.06
-0.02
-20.00%
AU:EVE
EVE Health Group Limited
0.02
-0.02
-52.50%
AU:CMB
Regeneus Ltd.
0.44
0.22
102.33%
AU:HIQ
HitIQ Limited
0.01
>-0.01
-28.57%
1st Group Ltd. Corporate Events
Visionflex Wins NSW Health Contract for Statewide Remote Monitoring Hardware
Jun 25, 2026
Visionflex Group Limited has secured an approximately $0.8 million contract with NSW Health to supply proprietary clinical hardware for the state’s Remote Patient Monitoring Digital Uplift program, supporting Virtual Hospital and Hospital in...
Visionflex Quarterly Cash Flow Shows Ongoing Operating Outflows
Apr 28, 2026
Visionflex Group Limited reported cash receipts from customers of A$778,000 for the March 2026 quarter, against operating outflows driven mainly by staff wages, administration, and manufacturing costs, resulting in negative operating cash flow of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.